Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash & Equivalents (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Cash & Equivalents for 4 consecutive years, with $490.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 36.51% to $490.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $490.0 million through Dec 2025, down 36.51% year-over-year, with the annual reading at $490.0 million for FY2025, 36.51% down from the prior year.
  • Cash & Equivalents hit $490.0 million in Q4 2025 for NewAmsterdam Pharma, down from $538.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $771.7 million in Q4 2024 to a low of $340.4 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $497.0 million across 4 years, with a median of $447.4 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 126.68% in 2024 and later crashed 36.51% in 2025.
  • Year by year, Cash & Equivalents stood at $447.4 million in 2022, then fell by 23.9% to $340.4 million in 2023, then skyrocketed by 126.68% to $771.7 million in 2024, then tumbled by 36.51% to $490.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for NAMS at $490.0 million in Q4 2025, $538.4 million in Q3 2025, and $563.9 million in Q2 2025.